TSX:APS (Canada)  
Aptose Biosciences Inc logo

Aptose Biosciences Inc

C$ 0.93 (-1.06%) Nov 25
P/E:
At Loss
P/B:
1.37
Market Cap:
C$ 85.83M ($ 64.05M)
Enterprise V:
C$ 12.31M ($ 9.18M)
Volume:
6.40K
Avg Vol (2M):
23.46K
Also Trade In:
Volume:
6.40K
Market Cap C$:
85.83M
Market Cap $:
64.05M
PE Ratio:
At Loss
Avg Vol (2-Month):
23.46K
Enterprise Value C$:
12.31M
Enterprise Value $:
9.18M
PB Ratio:
1.37
GF Score:
Year:
To
10Y: -%
Above Low: +NaN%
Below High: NaN%
Alerts Website Sources Stock Report
Dataset
Financial Download

Business Description

Description
Aptose Biosciences Inc is a clinical-stage biotechnology company committed to discovering and developing personalized therapies addressing unmet medical needs in oncology. The company has two clinical-stage programs and a second program that is discovery-stage and partnered with another company. Luxeptinib, its panFMS-like tyrosine kinase 3 / pan-Bruton's tyrosine kinase inhibitor, is enrolling patients in a Phase 1, multicenter, open label, dose-escalation study with expansions to assess the safety, tolerability, PK, and preliminary efficacy of CG-806 in patients with chronic lymphocytic leukemia (CLL/SLL) or non-Hodgkin lymphomas (NHL). HM43239 is an oral potent myeloid kinome inhibitor, targeting a constellation of kinases operative in myeloid malignancies.
Name Current Vs Industry Vs History
Cash-To-Debt 204.4
Equity-to-Asset 0.82
Debt-to-Equity 0.01
Debt-to-EBITDA -0.01
Interest Coverage N/A
N/A
N/A
Piotroski F-Score 2/9
0
1
2
3
4
5
6
7
8
9
Beneish M-Score -4.89
Manipulator
Not Manipulator
WACC vs ROIC
WACC
ROIC
Name Current Vs Industry Vs History
5-Day RSI 63.21
9-Day RSI 59.77
14-Day RSI 57.73
6-1 Month Momentum % -49.19
12-1 Month Momentum % -79

Liquidity Ratio

Name Current Vs Industry Vs History
Current Ratio 5.53
Quick Ratio 5.53
Cash Ratio 5.41

Dividend & Buy Back

Name Current Vs Industry Vs History
3-Year Average Share Buyback Ratio -34.2

Financials (Next Earnings Date:2023-03-22 Est.)

TSX:APS's 30-Y Financials

Guru Trades

See Details
To

Insider Trades

See Details
To

Peter Lynch Chart

Y-axis scale:
Interactive Chart
To

Performance

Dividend
Log
To

Annualized Return %

Symbol 1 Week 1 Month 3 Months 6 Months YTD 1 Year 3 Years 5 Years 10 Years

Total Annual Return %

Symbol 2022 2021 2020 2019 2018 2017 2016 2015 2014 2013

Executives

Valuation Box

Year:

Analyst Estimate

Key Statistics

Name Value
Revenue (TTM) (Mil C$)
EPS (TTM) (C$) -0.786
Beta 1.45
Volatility % 54.68
14-Day RSI 57.73
14-Day ATR (C$) 0.057007
20-Day SMA (C$) 0.8775
12-1 Month Momentum % -79
52-Week Range (C$) 0.62 - 3.07
Shares Outstanding (Mil) 92.29

Piotroski F-Score Details

Year:
Component Result
Piotroski F-Score 2
Positive ROA
Positive CFROA
Higher ROA yoy
CFROA > ROA
Lower Leverage yoy
Higher Current Ratio yoy
Less Shares Outstanding yoy
Higher Gross Margin yoy
Higher Asset Turnover yoy

Aptose Biosciences Inc Filings

Document Form Filing Date
No Filing Data

Aptose Biosciences Inc Analysis

Share your research